RANCHO CUCAMONGA, Calif., March 31, 2017 -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 12:50 p.m. Eastern Time in New York, NY.
This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com/events.cfm. This webcast will be available for 90 days following the presentation.
About Amphastar:
Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company’s finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company’s website at www.amphastar.com.
The Amphastar Pharmaceuticals’ logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene®, Amphadase® and Cortrosyn®, are the property of Amphastar Pharmaceuticals, Inc.
Forward-Looking Statement:
All statements in this press release and in the conference referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding future financial performance, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, acquisitions and other matters related to its pipeline of product candidates, its share buyback program and other future events. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates, and projections regarding Amphastar’s business, operations and other similar or related factors. Words such as “may,” “might”, “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission. You can locate these reports through the Company’s website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov. Amphastar undertakes no obligation to revise or update information in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause the Company’s expectations to change.
Contact: William J. Peters Chief Financial Officer (909) 476-3416


AFT Leaves X Over AI-Generated Images of Minors
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026
Starlink Internet Remains Active in Iran Despite Nationwide Blackout
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable”
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 



